GlassScriptPhysician profile
Hong Liang
NPI 1598784340
$5,737.16
in general payments reported to CMS, 2019-2025
26 companies · $932 in 2025
The $932 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $327 · 2021: $948 · 2022: $754 · 2023: $1,104 · 2024: $952 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,971 · Education: $17.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.14 |
| Education | $17.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $938.00 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $799.59 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $504.48 | 2021-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $351.92 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $347.23 | 2019-2025 | Verquvo, Capvaxive, Steglatro |
| Abbvie INC. | $328.64 | 2019-2025 | |
| Redhill Biopharma INC. | $321.28 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Astellas Pharma US INC | $307.22 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.74 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $221.59 | 2020-2021 | |
| Almatica Pharma LLC | $206.31 | 2023-2024 | Loreev Xr, Gralise, Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $181.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $170.13 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.40 | 2021-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $133.54 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $114.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $107.79 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $46.05 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $42.46 | 2022-2023 | Eliquis |
| Lilly USA, LLC | $40.99 | 2024 | Jardiance |
| Gilead Sciences, INC. | $37.62 | 2019 | |
| Dermira, INC. | $19.20 | 2020 | |
| Allergan, INC. | $19.15 | 2019 | |
| Ibsa Pharma INC. | $19.11 | 2021 | |
| Eisai INC. | $18.24 | 2022 | |
| Pfizer INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.